Basic Information

Gene symbol MLANA Synonyms MART-1, MART1 Type of gene protein-coding
Description melan-A

GTO ID GTC0041
Trial ID NCT00509288
Disease Metastatic Melanoma
Altered gene MART-1
Therapeutic/Target gene Target gene
TherapyTCR-T cell
Treatment MAGE-A1 F5 TCR-T cells
HLAHLA-A*02:01
PhasePhase2
Recruitment statusCompleted
TitlePhase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes
Year2007
CountryUnited States
Company sponsorNational Cancer Institute (NCI)
Other ID(s)070175|07-C-0175
Vector information
Vectorretrovirus
Transgene/Inserted geneDMF5 TCR-α cDNA; furin T2A cleavage sequence; DMF5 TCR-β cDNA
Viral genome modificationpMSGV1 is derived from pMSGV murine stem cell virus long terminal repeat containing an extended gag region and Kozak sequence. Vector pMSGV1 gp100(154)-AIB was produced by linking the TCR-α via an internal ribosome entry site (IRES) element followed by insertion of the TCR-β chain. Vector pMSGV DMF5 furin 2-A was generated by introducing DMF5 TCR-α cDNA, followed by a furin T2A cleavage sequence and DMF5 TCR-β.

Clinical Result

Cohort1: TCR PBLs
Administration route infusion
Dosage 5E8~3E11 cells
Donor type autologous
Pts 21
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 6/21(PR); 15/21(PD)
Adverse reactions 3/21(Infections and infestations; Metabolism and nutrition disorders; Nervous system disorders; Renal and urinary disorders; Skin and subcutaneous tissue disorders; Vascular disorders)
References PMID: 19451549
Cohort2: TCR TILs
Administration route infusion
Dosage 5E8~3E11 cells
Donor type autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 2/3(PD)
Adverse reactions 1/3(Nervous system disorders)
References PMID: 19451549

Relationship Graph

Overview of Knowledge Graph